{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:33:38Z","timestamp":1776119618446,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1038\/89901","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T08:50:09Z","timestamp":1027673409000},"page":"781-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":405,"title":["Replication-selective virotherapy for cancer: Biological principles, risk management and future directions"],"prefix":"10.1038","volume":"7","author":[{"given":"David","family":"Kirn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Martuza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Zwiebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnm0701_781_CR1","first-page":"656","volume":"22","author":"CM Southam","year":"1960","unstructured":"Southam, C.M. Present status of oncolytic virus studies. NY Acad. Sci. 22, 656\u2013673 (1960).","journal-title":"NY Acad. Sci."},{"key":"BFnm0701_781_CR2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. & Coen, D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854\u2013856 (1991).","journal-title":"Science"},{"key":"BFnm0701_781_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1172\/JCI9761","volume":"105","author":"D Kirn","year":"2000","unstructured":"Kirn, D. Replication-selective microorganisms: Fighting cancer with targeted germ warfare. J. Clin. Invest. 105, 836\u2013838 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0701_781_CR4","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.1038\/sj.onc.1204094","volume":"19","author":"D Kirn","year":"2000","unstructured":"Kirn, D. Replication\u2013selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer. Oncogene 19, 6660\u20136668 (2000).","journal-title":"Oncogene"},{"key":"BFnm0701_781_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1172\/JCI9744","volume":"105","author":"R Martuza","year":"2000","unstructured":"Martuza, R. Conditionally replicating herpes viruses for cancer therapy. J. Clin. Invest. 105, 841\u2013846 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0701_781_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1172\/JCI9871","volume":"105","author":"K Norman","year":"2000","unstructured":"Norman, K. & Lee, P. Reovirus as a novel oncolytic agent. J. Clin. Invest. 105, 1035\u20131038 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0701_781_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1172\/JCI9819","volume":"105","author":"M Mastrangelo","year":"2000","unstructured":"Mastrangelo, M., Eisenlohr, L., Gomella, L. & Lattime, E. Poxvirus vectors: Orphaned and underappreciated. J. Clin. Invest. 105, 1031\u20131034 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0701_781_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/jnci\/80.16.1305","volume":"80","author":"RM Lorence","year":"1988","unstructured":"Lorence, R.M., Rood, P.A. & Kelley, K.W. Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor-\u03b1 and augmentation of its cytotoxicity. J. Natl. Cancer. Inst. 80, 1305\u20131312 (1988).","journal-title":"J. Natl. Cancer. Inst."},{"key":"BFnm0701_781_CR9","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","volume":"282","author":"M Coffey","year":"1998","unstructured":"Coffey, M., Strong, J., Forsyth, P. & Lee, P. Reovirus therapy of tumors with activated ras pathway, Science 282, 1332\u20131334 (1998).","journal-title":"Science"},{"key":"BFnm0701_781_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/77558","volume":"6","author":"DF Stojdl","year":"2000","unstructured":"Stojdl, D.F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Med. 6, 821\u2013825 (2000).","journal-title":"Nature Med."},{"key":"BFnm0701_781_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0166-0934(91)90024-T","volume":"33","author":"J Rommelaere","year":"1991","unstructured":"Rommelaere, J. & Cornelis, J.J. Antineoplastic activity of parvoviruses. J. Virol. Meth. 33, 233\u2013251 (1991).","journal-title":"J. Virol. Meth."},{"key":"BFnm0701_781_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. & Coen, D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 252, 854\u2013856 (1991).","journal-title":"Science."},{"key":"BFnm0701_781_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff, J.R. et al. An adenovirus mutant that replicates selectively in p53\u2013deficient human tumor cells. Science 274, 373\u2013376 (1996).","journal-title":"Science"},{"key":"BFnm0701_781_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nm0697-639","volume":"3","author":"C Heise","year":"1997","unstructured":"Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3, 639\u2013645 (1997).","journal-title":"Nature Med."},{"key":"BFnm0701_781_CR15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/80474","volume":"6","author":"C Heise","year":"2000","unstructured":"Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nature Med. 6, 1134\u20131139 (2000).","journal-title":"Nature Med."},{"key":"BFnm0701_781_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","volume":"19","author":"J Fueyo","year":"2000","unstructured":"Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2\u201312 (2000).","journal-title":"Oncogene"},{"key":"BFnm0701_781_CR17","doi-asserted-by":"publisher","first-page":"6803","DOI":"10.1073\/pnas.97.12.6803","volume":"97","author":"M Gromeier","year":"2000","unstructured":"Gromeier, M., Lachmann, S., Rosenfeld, M.R., Gutin, P.H. & Wimmer, E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. USA 97, 6803\u20136808 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0701_781_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1089\/10430349950017725","volume":"10","author":"P Hallenbeck","year":"1999","unstructured":"Hallenbeck, P. et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10, 1721\u20131733 (1999).","journal-title":"Hum. Gene Ther."},{"key":"BFnm0701_781_CR19","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1128\/jvi.71.7.5124-5132.1997","volume":"71","author":"S Miyatake","year":"1997","unstructured":"Miyatake, S., Iyer, A., Martuza, R.L. & Rabkin, S.D., Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 71, 5124\u20131532 (1997).","journal-title":"J. Virol."},{"key":"BFnm0701_781_CR20","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1128\/jvi.71.11.8221-8229.1997","volume":"71","author":"TJ Wickham","year":"1997","unstructured":"Wickham T.J. et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins, J. Virol. 71, 8221\u20138229 (1997).","journal-title":"J. Virol."},{"key":"BFnm0701_781_CR21","first-page":"3395","volume":"6","author":"N Alemany","year":"2000","unstructured":"Alemany, N. & Curiel, D.T., The development of replicative adenoviruses for cancer therapy, Clin. Cancer Res. 6, 3395\u20133399 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnm0701_781_CR22","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","volume":"17","author":"J Strong","year":"1998","unstructured":"Strong, J., Coffey, M., Tang, D., Sabinin, P. & Lee, P., The molecular basis of viral oncolysis: usurpation of the ras signaling pathway by reovirus. EMBO J. 17, 3351\u20133362 (1998).","journal-title":"EMBO J."},{"key":"BFnm0701_781_CR23","doi-asserted-by":"publisher","first-page":"8702","DOI":"10.1073\/pnas.90.18.8702","volume":"90","author":"A Telerman","year":"1993","unstructured":"Telerman, A. et al. A model for tumor suppression using H\u20131 parvovirus. Proc. Natl. Acad. Sci. USA 90, 8702\u20138706 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0701_781_CR24","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1172\/JCI116527","volume":"91","author":"RJ Whitley","year":"1993","unstructured":"Whitley, R.J., Kern, E.R., Chatterjee, S., Chou, J. & Roizman, B. Replication, establishment of latency, and induced reactivation of herpes simplex virus \u03b3 1 34.5 deletion mutants in rodent models. J. Clin. Invest. 91, 2837\u20132843 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnm0701_781_CR25","first-page":"3963","volume":"54","author":"T Mineta","year":"1994","unstructured":"Mineta, T., Rabkin, S.D. & Martuza, R.L. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963\u20133966 (1994).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR26","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm0995-938","volume":"1","author":"T Mineta","year":"1995","unstructured":"Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D. & Martuza, R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938\u2013943 (1995).","journal-title":"Nature Med."},{"key":"BFnm0701_781_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/jvi.62.1.257-265.1988","volume":"62","author":"P Whyte","year":"1988","unstructured":"Whyte, P., Ruley, H. & Harlow, E. Two regions of the adenovirus early region 1A proteins are required for transformation. J. Virol. 62, 257\u2013265 (1988).","journal-title":"J. Virol."},{"key":"BFnm0701_781_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0042-6822(87)90441-7","volume":"156","author":"DD Barker","year":"1987","unstructured":"Barker, D.D. & Berk, A.J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107\u2013121 (1987).","journal-title":"Virology"},{"key":"BFnm0701_781_CR29","first-page":"6359","volume":"60","author":"J Nemunaitis","year":"2000","unstructured":"Nemunaitis, J. et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial. Cancer Res. 60, 6359\u20136366 (2000).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR30","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1128\/JVI.73.7.5333-5344.1999","volume":"73","author":"J Harada","year":"1999","unstructured":"Harada, J. & Berk, A. p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication. J. Virology. 73, 5333\u20135344 (1999).","journal-title":"J. Virology."},{"key":"BFnm0701_781_CR31","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1128\/JVI.72.12.9470-9478.1998","volume":"72","author":"T Rothmann","year":"1998","unstructured":"Rothmann, T., Hengstermann, A., Whitaker, N.J., Scheffner, M. & zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72, 9470\u20139478 (1998).","journal-title":"J. Virol."},{"key":"BFnm0701_781_CR32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/jvi.71.1.548-561.1997","volume":"71","author":"FD Goodrum","year":"1997","unstructured":"Goodrum, F.D. & Ornelles, D.A. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol. 71, 548\u2013561 (1997).","journal-title":"J Virol."},{"key":"BFnm0701_781_CR33","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/80466","volume":"6","author":"SJ Ries","year":"2000","unstructured":"Ries, S.J. et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX\u2013015). Nature Med. 6, 1128\u20131133 (2000).","journal-title":"Nature Med."},{"key":"BFnm0701_781_CR34","volume-title":"Proceedings of Cancer Gene Therapy Meeting San Diego","author":"D Kirn","year":"1998","unstructured":"Kirn, D., Heise, C., Williams, M., Propst, M. & Hermiston, T. Adenovirus E1A CR2 mutants as selectively replicating agents for cancer. in Proceedings of Cancer Gene Therapy Meeting San Diego (abstract) (1998)."},{"key":"BFnm0701_781_CR35","volume-title":"Virology","author":"B Moss","year":"1996","unstructured":"Moss, B. Poxiviridae: The viruses and their replication. in Virology, 3rd ed. (ed. Fields, B.N.) (Lippincott\u2013Raven Publishers, Philadelphia, 1996)."},{"key":"BFnm0701_781_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.cgt.7700075","volume":"7","author":"M Puhlmann","year":"2000","unstructured":"Puhlmann, M. et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7, 66\u201373 (2000).","journal-title":"Cancer Gene Ther."},{"key":"BFnm0701_781_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.cgt.7700066","volume":"6","author":"MJ Mastrangelo","year":"1999","unstructured":"Mastrangelo, M.J. et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma, Cancer Gene Ther. 6, 409\u2013422 (1999).","journal-title":"Cancer Gene Ther."},{"key":"BFnm0701_781_CR38","first-page":"2559","volume":"57","author":"R Rodriguez","year":"1997","unstructured":"Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559\u20132563 (1997).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1172\/JCI9180","volume":"106","author":"T Kurihara","year":"2000","unstructured":"Kurihara, T., Brough, D.E., Kovesdi, I. & Kufe, D.W., Selectivity of a replication\u2013competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen, J. Clin. Invest. 106, 763\u2013771 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0701_781_CR40","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1128\/JVI.75.6.2972-2981.2001","volume":"75","author":"J Jakubczak","year":"2001","unstructured":"Jakubczak, J. et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B\u2013adenovirus receptor\u2013bearing cells, J. Virol. 75, 2972\u20132981 (2001).","journal-title":"J. Virol."},{"key":"BFnm0701_781_CR41","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1126\/science.286.5444.1568","volume":"286","author":"P Roelvink","year":"1999","unstructured":"Roelvink, P., Mi, G., Einfeld, D., Kovesdi, I. & Wickham, T. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science. 286, 1568\u20131571 (1999).","journal-title":"Science."},{"key":"BFnm0701_781_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/sj.gt.3301377","volume":"8","author":"D Kirn","year":"2001","unstructured":"Kirn, D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 8, 89\u201398 (2001).","journal-title":"Gene Ther."},{"key":"BFnm0701_781_CR43","first-page":"1512","volume":"19","author":"P Vasey","year":"2000","unstructured":"Vasey, P., Shulman, L., Gore, M., Kirn, D. & Kaye, S. Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian carcinoma. Proceedings of the American Society of Clinical Oncology 19, 1512 (2000).","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"BFnm0701_781_CR44","first-page":"953","volume":"19","author":"T Reid","year":"2000","unstructured":"Reid, T. et al. Hepatic artery infusion of Onyx-015, a replication-selective adenovirus, in combination with 5-FU\/leucovorin for gastrointestinal carcinoma metastatic to the liver: A Phase I\/II clinical trial. Proceedings of the American Society of Clinical Oncology. 19, 953 (2000).","journal-title":"Proceedings of the American Society of Clinical Oncology."},{"key":"BFnm0701_781_CR45","unstructured":"Nemunaitis, J., Cunningham, C., Randlev, B. & Kirn, D. A Phase I dose escalation trial of intravenous infusion with a replication-selective adenovirus, dl 1520, in patients with refractory cancer. Gene Ther. (in the press)."},{"key":"BFnm0701_781_CR46","first-page":"4200","volume":"59","author":"D Yu","year":"1999","unstructured":"Yu, D., Chen, Y., Seng, M., Dilley, J. & Henderson, D.R. The addition of adenovirus region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59, 4200\u20134203 (1999).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR47","first-page":"1039","volume":"19","author":"R Hecht","year":"2000","unstructured":"Hecht, R. et al. A Phase I\/ II trial of intratumoral endoscopic injection of Onyx-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Proceedings of the American Society of Clinical Oncology. 19, 1039 (2000).","journal-title":"Proceedings of the American Society of Clinical Oncology."},{"key":"BFnm0701_781_CR48","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/78638","volume":"6","author":"F Khuri","year":"2000","unstructured":"Khuri, F. et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nature Med. 6, 879\u2013885 (2000).","journal-title":"Nature Med."},{"key":"BFnm0701_781_CR49","first-page":"517","volume":"61","author":"D Yu","year":"2001","unstructured":"Yu, D. et al. Antitumor synergy of CN787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 61, 517\u2013525 (2001).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR50","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.gt.3301205","volume":"7","author":"J Markert","year":"2000","unstructured":"Markert, J. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a Phase I trial. Gene Therapy. 7, 867\u2013874 (2000).","journal-title":"Gene Therapy."},{"key":"BFnm0701_781_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.gt.3301184","volume":"7","author":"R Rampling","year":"2000","unstructured":"Rampling, R. et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 1\u20134 (2000).","journal-title":"Gene Ther."},{"key":"BFnm0701_781_CR52","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/11320","volume":"5","author":"K Ikeda","year":"1999","unstructured":"Ikeda, K. & Chiocca, N. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited anti-viral responses. Nature Med. 5, 881\u2013887 (1999).","journal-title":"Nature Med."},{"key":"BFnm0701_781_CR53","first-page":"2330","volume":"5","author":"RM Conry","year":"1999","unstructured":"Conry, R.M. et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration, Clin. Cancer Res. 5, 2330\u20132337 (1999).","journal-title":"Clin. Cancer Res."},{"key":"BFnm0701_781_CR54","first-page":"1632","volume":"6","author":"JP Eder","year":"2000","unstructured":"Eder, J.P. et al. A Phase I trial of a recombinant vaccinia virus expressing prostate\u2013specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632\u20131638 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnm0701_781_CR55","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/sj.cgt.7700133","volume":"7","author":"S Mukherjee","year":"2000","unstructured":"Mukherjee, S. et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther. 7, 663\u2013670 (2000).","journal-title":"Cancer Gene Ther."},{"key":"BFnm0701_781_CR56","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO;2-4","volume":"52","author":"WA Cassel","year":"1983","unstructured":"Cassel, W.A., Murray, D.R. & Phillips, H.S. A Phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer. 52, 856\u2013860 (1983).","journal-title":"Cancer."},{"key":"BFnm0701_781_CR57","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/BF03401771","volume":"4","author":"FM Batliwalla","year":"1998","unstructured":"Batliwalla, F.M. et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol. Med. 4, 783\u2013794 (1998).","journal-title":"Mol. Med."},{"key":"BFnm0701_781_CR58","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF01771453","volume":"32","author":"B Lehner","year":"1990","unstructured":"Lehner, B., Schlag, P., Liebrich, W. & Schirrmacher, V. Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine, Cancer Immunol. Immunother. 32, 173\u2013178 (1990).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnm0701_781_CR59","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0277-5379(91)90170-I","volume":"27","author":"W Liebrich","year":"1991","unstructured":"Liebrich, W. et al. In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur. J. Cancer 27, 703\u2013710 (1991).","journal-title":"Eur. J. Cancer"},{"key":"BFnm0701_781_CR60","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/sj.cgt.7700071","volume":"6","author":"C Heise","year":"1999","unstructured":"Heise, C., Williams, A., Olesch, J. & Kirn, D. Efficacy of a replication-competent adenovirus (ONYX\u2013015) following intratumoral injection: Intratumoral spread and distribution effects. Cancer Gene Ther. 6, 499\u2013504 (1999).","journal-title":"Cancer Gene Ther."},{"key":"BFnm0701_781_CR61","first-page":"813","volume":"61","author":"J Douglas","year":"2001","unstructured":"Douglas, J., Kim, M., Sumerel, L., Carey, D. & Curiel, D. Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res. 61, 813\u2013817 (2001).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR62","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1089\/10430349950016483","volume":"10","author":"T Toda","year":"1999","unstructured":"Toda, T. et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10, 2741\u20132755 (1999).","journal-title":"Hum. Gene Ther."},{"key":"BFnm0701_781_CR63","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/sj.gt.3300643","volume":"5","author":"U Herrlinger","year":"1998","unstructured":"Herrlinger, U. et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. 5, 809\u2013819 (1998).","journal-title":"Gene Ther."},{"key":"BFnm0701_781_CR64","first-page":"798","volume":"6","author":"I Ganly","year":"2000","unstructured":"Ganly, I. et al. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798\u2013806 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnm0701_781_CR65","first-page":"2623","volume":"59","author":"C Heise","year":"1999","unstructured":"Heise, C., Williams, A., Xue, S., Propst, M. & Kirn, D. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59, 2623\u20132628 (1999).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR66","first-page":"1193","volume":"60","author":"K Rogulski","year":"2000","unstructured":"Rogulski, K. et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy, Cancer Res. 60, 1193\u20131196 (2000).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR67","first-page":"4908","volume":"6","author":"C Heise","year":"2000","unstructured":"Heise, C., Lemmon, M. & Kirn, D. Replication-selective adenovirus plus cisplatin chemotherapy efficacy is dependent on sequencing but independent of p53 status. Clin. Cancer Res. 6, 4908\u20134914 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnm0701_781_CR68","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.neo.7900016","volume":"1","author":"A Chalavi","year":"1999","unstructured":"Chalavi, A., Todo, T., Martuza, R. & Rabkin, S. Replication-competent herpes simplex vector G207\/cisplatin combination therapy for head and neck squamous cell carcinoma, Neoplasia. 1, 162\u2013169 (1999).","journal-title":"Neoplasia."},{"key":"BFnm0701_781_CR69","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/BF00205606","volume":"26","author":"JS Bryson","year":"1988","unstructured":"Bryson, J.S. & Cox, D.C., Characteristics of reovirus\u2013mediated chemoimmunotherapy of murine L1210 leukemia. Cancer Immunol. Immunother. 26, 132\u2013138 (1988).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnm0701_781_CR70","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1128\/JVI.74.13.6147-6155.2000","volume":"74","author":"K Doronin","year":"2000","unstructured":"Doronin, K. et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virology 74, 6147\u20136155 (2000).","journal-title":"J. Virology"},{"key":"BFnm0701_781_CR71","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/10430340050015851","volume":"11","author":"H Sauthoff","year":"2000","unstructured":"Sauthoff, H., Heitner, S., Rom, W. & Hay, J., Deletion of the adenoviral E1B\u201319kD gene enhances tumor cell killing of a replicating adenoviral vector, Hum. Gene Ther. 11, 379\u2013388 (2000).","journal-title":"Hum. Gene Ther."},{"key":"BFnm0701_781_CR72","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1172\/JCI9973","volume":"105","author":"T Hermiston","year":"2000","unstructured":"Hermiston, T. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J. Clin. Invest. 105, 1169\u20131172 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0701_781_CR73","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.4049\/jimmunol.160.9.4457","volume":"160","author":"M Toda","year":"1998","unstructured":"Toda, M., Martuza, R.L., Kojima, H. & Rabkin, S.D. In situ cancer vaccination: An IL-12 defective vector\/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457\u20134464 (1998).","journal-title":"J. Immunol"},{"key":"BFnm0701_781_CR74","first-page":"410","volume":"59","author":"O Wildner","year":"1999","unstructured":"Wildner, O., Blaese, R.M. & Morris, J.M. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 59, 410\u2013413 (1999).","journal-title":"Cancer Res."},{"key":"BFnm0701_781_CR75","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1089\/hum.1998.9.9-1323","volume":"9","author":"SO Freytag","year":"1998","unstructured":"Freytag, S.O., Rogulski, K. R., Paielli, D.L., Gilbert, J.D. & Kim, J.H. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323\u20131333 (1998).","journal-title":"Hum. Gene Ther."},{"key":"BFnm0701_781_CR76","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/0140-6736(92)90698-3","volume":"339","author":"SJ Russell","year":"1992","unstructured":"Russell, S.J. Gene therapy for cancer, Lancet. 339, 1109\u2013110 (1992)","journal-title":"Lancet."},{"key":"BFnm0701_781_CR77","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1089\/10430340050015789","volume":"11","author":"A Haag","year":"2000","unstructured":"Haag, A. et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum. Gene Ther. 11, 597\u2013609 (2000).","journal-title":"Hum. Gene Ther."},{"key":"BFnm0701_781_CR78","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/sj.gt.3301237","volume":"7","author":"JA McCart","year":"2000","unstructured":"McCart, J.A. et al. Complex interactions between the replicating oncolytic effect and the enzyme\/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 7, 1217\u20131223 (2000).","journal-title":"Gene Ther."},{"key":"BFnm0701_781_CR79","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1172\/JCI9818","volume":"105","author":"M Sznol","year":"2000","unstructured":"Sznol, M., Lin, S., Bermudes, D., Zheng, L. & King, I. Use of preferentially replicating bacteria for the treatment of cancer. J. Clin. Invest. 105, 1027\u20131030 (2000).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nm0701_781.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm0701_781","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm0701_781.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:42:33Z","timestamp":1743802953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm0701_781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["BFnm0701_781"],"URL":"https:\/\/doi.org\/10.1038\/89901","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}